To determine whether the twice‐daily (BID) regimen is superior to the once‐daily (QD) regimen for managing glycaemic variability by comparing the effects of anagliptin 100 mg BID versus sitagliptin 100 mg QD. Click to show full abstract
To determine whether the twice‐daily (BID) regimen is superior to the once‐daily (QD) regimen for managing glycaemic variability by comparing the effects of anagliptin 100 mg BID versus sitagliptin 100 mg QD.
               
Click one of the above tabs to view related content.